Prescribing for people with acute rheumatic fever

Ralph, Anna P.; Noonan, Sara; Boardman, Claire; Halkon, Catherine; Currie, Bart J.

doi:10.18773/austprescr.2017.011

Cited by 11 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Traditionally, moon phases have been used as a guide for patients to recall when their needle is due; calendars and reminder cards are also used, and a smartphone application is also now available. [ 14 ]…”

Section: Discussionmentioning

confidence: 99%

Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data

et al. 2017

View full text Add to dashboard Cite

ObjectiveIn high-burden Australian states and territories, registers of patients with acute rheumatic fever and rheumatic heart disease are maintained for patient management, monitoring of system performance and research. Data validation was undertaken for the Australian Northern Territory Rheumatic Heart Disease Register to determine quality and impact of data cleaning on reporting against key performance indicators: overall adherence, and proportion of patients receiving ≥80% of scheduled penicillin doses for secondary prophylaxis.MethodsRegister data were compared with data from health centres. Inconsistencies were identified and corrected; adherence was calculated before and after cleaning.Results2780 penicillin doses were validated; 426 inconsistencies were identified, including 102 incorrect dose dates. After cleaning, mean adherence increased (63.5% to 67.3%, p<0.001) and proportion of patients receiving ≥80% of doses increased (34.2% to 42.1%, p = 0.06).ConclusionsThe Northern Territory Rheumatic Heart Disease Register underestimates adherence, although the key performance indicator of ≥80% adherence was not significantly affected. Program performance is better than hitherto appreciated. However some errors could affect patient management, as well as accuracy of longitudinal or inter-jurisdictional comparisons. Adequate resources are needed for maintenance of data quality in acute rheumatic fever/rheumatic heart disease registers to ensure provision of evidence-based care and accurate assessment of program impact.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data

et al. 2017

View full text Add to dashboard Cite

show abstract

“…At intermediate-to-high doses (650 mg to 4 g/day), ASA is able to irreversibly inhibit both COX-1 and COX-2, and at these doses ASA has been used for treating severe inflammatory disorders (e.g., rheumatic fever, Kawasaki disease, adult-onset Still's disease, and recurrent pericarditis) [69][70][71][72][73][74]. Significant improvement of some inflammation-related symptoms (e.g., fever, joint symptoms) and reductions of plasma levels of inflammation markers (e.g., white blood cell count, erythrocyte sedimentation rate, and C-reactive protein) have been obtained with the use of intermediate-to-high doses of ASA in all the aforementioned conditions [69][70][71][72][73][74]. In addition, a single high dose of ASA has improved symptoms related to both the common cold and flu, including fever, myalgias, headache, and sore throat [75,76].…”

Section: Acetylsalicylic Acid As An Anti-inflammatory Drugmentioning

confidence: 99%

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Bianconi

Violi

Fallarino

et al. 2020

Drugs

115

134

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome–Coronavirus-2 is responsible for the current pandemic that has led to more than 10 million confirmed cases of Coronavirus Disease-19 (COVID-19) and over 500,000 deaths worldwide (4 July 2020). Virus-mediated injury to multiple organs, mainly the respiratory tract, activation of immune response with the release of pro-inflammatory cytokines, and overactivation of the coagulation cascade and platelet aggregation leading to micro- and macrovascular thrombosis are the main pathological features of COVID-19. Empirical multidrug therapeutic approaches to treat COVID-19 are currently used with extremely uncertain outcomes, and many others are being tested in clinical trials. Acetylsalicylic acid (ASA) has both anti-inflammatory and antithrombotic effects. In addition, a significant ASA-mediated antiviral activity against DNA and RNA viruses, including different human coronaviruses, has been documented. The use of ASA in patients with different types of infections has been associated with reduced thrombo-inflammation and lower rates of clinical complications and in-hospital mortality. However, safety issues related both to the risk of bleeding and to that of developing rare but serious liver and brain damage mostly among children (i.e., Reye’s syndrome) should be considered. Hence, whether ASA might be a safe and reasonable therapeutic candidate to be tested in clinical trials involving adults with COVID-19 deserves further attention. In this review we provide a critical appraisal of current evidence on the anti-inflammatory, antithrombotic, and antiviral effects of ASA, from both a pre-clinical and a clinical perspective. In addition, the potential benefits and risks of use of ASA have been put in the context of the adult-restricted COVID-19 population.

show abstract

“…In the studies, aspirin treatment was primarily adopted as an antiinflammatory treatment in patients with arthritis and mild carditis, however, the use of other non-steroidal anti-inflammatory drugs in case of aspirin intolerance is mentioned. [11][12][13] Cetin et al 14 reported that they discontinued aspirin and administered naproxen because of aspirin-induced hepatotoxicity in 10% of children with acute rheumatic fever. In the study of Karademir et al 15 they reported that tolmetin can be used effectively and safely in patients who cannot tolerate aspirin treatment.…”

Section: Discussionmentioning

confidence: 99%

Aspirin-induced hepatotoxicity and anemia in children with acute rheumatic fever

Altay¹,

Pamukçu²,

Baykan³

et al. 2021

Turk J Pediatr

View full text Add to dashboard Cite

Background. The aim of this study was to investigate the frequency of anemia and hepatotoxicity associated with aspirin use in patients with acute rheumatic fever. Methods.Patients with acute rheumatic fever followed at Erciyes University, Faculty of Medicine, Department of Pediatric Cardiology between 2015-2018 were reviewed retrospectively.Results. A total of 286 patients with acute rheumatic fever were analysed. Aspirin treatment was started in 53 of the 286 patients (18.5%) due to arthritis. The mean age of the patients who used aspirin was 10.7 ± 2.5 years. Aspirin-induced hepatotoxicity developed in 9 (17%) of the 53 patients. Naproxen or ibuprofen was given to these patients as an alternative to aspirin. No side effects occurred in patients receiving naproxen or ibuprofen. In addition, 30% of 53 patients were initially anemic. The mean duration of aspirin use in the hepatotoxic patients who had anemia was longer than patients without anemia (p=0.02). Conclusions.Patients with acute rheumatic fever should be closely monitored for aspirin hepatotoxicity. When aspirin hepatotoxicity develops, naproxen or ibuprofen treatment can be used safely.

show abstract

Prescribing for people with acute rheumatic fever

Cited by 11 publications

References 28 publications

Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data

Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Aspirin-induced hepatotoxicity and anemia in children with acute rheumatic fever

Contact Info

Product

Resources

About